187 related articles for article (PubMed ID: 35755959)
1. Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata: A split-scalp, double-blind, controlled study.
Thuangtong R; Suvansuthi S; Maneeprasopchoke P; Sukakul T; Techakajornkeart R; Chaweekulrat P; Wongdama S; Triwongwaranat D
Int J Trichology; 2022; 14(3):91-96. PubMed ID: 35755959
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
3. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Kagami S; Kishi Y; Hino H
J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
Ibrahim SA; Esawy AM; Abdelshafy AS
Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H
Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
Ghandi N; Daneshmand R; Hatami P; Abedini R; Nasimi M; Aryanian Z; Vance TM
Int Immunopharmacol; 2021 Oct; 99():107971. PubMed ID: 34298402
[TBL] [Abstract][Full Text] [Related]
7. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata.
Wasyłyszyn T; Borowska K
Australas J Dermatol; 2017 Aug; 58(3):219-223. PubMed ID: 27087586
[TBL] [Abstract][Full Text] [Related]
8. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low-level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow-up based on clinical studies.
Behrangi E; Roohaninasab M; Sadeghzadeh-Bazargan A; Najar Nobari N; Ghassemi M; Seirafianpour F; Goodarzi A; Dodangeh M
J Cosmet Dermatol; 2022 Jul; 21(7):2727-2741. PubMed ID: 34606676
[TBL] [Abstract][Full Text] [Related]
9. Extensive alopecia areata: not necessarily recalcitrant to therapy!
Deshpande D; Dhurat R; Saraogi P; Mishra S; Nayak C
Int J Trichology; 2011 Jul; 3(2):80-3. PubMed ID: 22223966
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
Özdemir M; Balevi A
Pediatr Dermatol; 2017 Mar; 34(2):128-132. PubMed ID: 28044367
[TBL] [Abstract][Full Text] [Related]
11. Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata.
Krueger L; Peterson E; Shapiro J; Lo Sicco K
JAAD Case Rep; 2019 Mar; 5(3):258-260. PubMed ID: 30891474
[No Abstract] [Full Text] [Related]
12. A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population.
Zafrir Y; Tantuco K; Tangtatco AJA; Ho N
J Cutan Med Surg; 2023; 27(5):449-453. PubMed ID: 37559401
[TBL] [Abstract][Full Text] [Related]
13. Treatment Response to Diphenylcyclopropenone in Patients with Alopecia Totalis/Universalis.
Varghese SA; Nair SS; George AE; Yadev I
Int J Trichology; 2023; 15(4):149-153. PubMed ID: 38765726
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.
Wu SZ; Wang S; Ratnaparkhi R; Bergfeld WF
Pediatr Dermatol; 2018 Nov; 35(6):817-820. PubMed ID: 30338548
[TBL] [Abstract][Full Text] [Related]
15. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
16. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases.
Pericin M; Trüeb RM
Dermatology; 1998; 196(4):418-21. PubMed ID: 9669118
[TBL] [Abstract][Full Text] [Related]
17. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
[TBL] [Abstract][Full Text] [Related]
18. Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
Hon KL; Luk DCK; Leung AKC; Ng C; Loo SKF
Recent Pat Inflamm Allergy Drug Discov; 2020; 14(2):117-132. PubMed ID: 32723274
[TBL] [Abstract][Full Text] [Related]
19. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata--a large retrospective study on 142 patients with a self-controlled design.
Ohlmeier MC; Traupe H; Luger TA; Böhm M
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):503-7. PubMed ID: 21569118
[TBL] [Abstract][Full Text] [Related]
20. Extensive scalp angioedema following high-dose diphenylcyclopropenone for alopecia areata.
Buchanan R; Huynh G; Tanner J
Hosp Pharm; 2014 Jan; 49(1):48-51. PubMed ID: 24421563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
